Related Experiment Videos
[Therapy and course of dilated cardiomyopathy]
Insights
Dilated cardiomyopathy causes severe heart failure and enlarged heart chambers. This condition has a poor prognosis, with a 5-year survival rate of only 38%.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Dilated cardiomyopathy is a primary myocardial disease with unknown etiology.
- Characterized by severe systolic dysfunction, cardiac chamber dilation, and cardiomegaly.
- Clinical manifestations include congestive heart failure, with cardiomegaly and arrhythmia potentially preceding symptoms.
Purpose:
- To describe the clinical features, therapeutic approaches, and prognosis of dilated cardiomyopathy.
Summary:
- Dilated cardiomyopathy presents with significant pump failure and enlarged heart chambers.
- Medical management involves standard congestive heart failure treatments (digitalis, diuretics) and afterload-reducing agents (ACE inhibitors).
- Antiarrhythmic drugs and anticoagulation are used for specific complications like severe arrhythmia or atrial fibrillation.
Impact:
- Dilated cardiomyopathy typically follows a poor clinical course.
- The 5-year survival rate in affected patients is approximately 38%.
Abstract:
Dilated cardiomyopathy is a primary myocardial disease of unknown origin. The typical findings are severe systolic pump failure and dilatation of all cardiac chambers with severe cardiomegaly. Clinical symptomatology is determined by myocardial dysfunction with congestive heart failure. Cardiomegaly and arrhythmia may precede clinical symptoms of congestive heart failure by years. Medical therapy is based on classical treatment of congestive heart failure with digitalis and diuretics; recently, afterload-reducing agents, such as converting enzyme inhibitors, have become the drug of choice for patients with severe congestive heart failure. Antiarrhythmic therapy is necessary in the presence of severe arrhythmia, and anticoagulation is indicated when a low-output state or atrial fibrillation are present. Clinical course in dilated cardiomyopathy is usually poor and 5-year survival is 38% in our group.